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Abstract
Postpartum psychosis is a severe psychiatric condition 
which affects 1-2 of every 1000 mothers shortly after 
childbirth. Whilst there is convincing evidence that the 
condition is precipitated by a complex combination of 
biological and environmental factors, as yet the patho-
physiological mechanisms remain extremely poorly 
defined. Here, I critically review approaches that have 
been, or are being, employed to identify and characterise 
such mechanisms; I also review a recent animal model 
approach, and describe a novel biological risk model that 
it suggests. Clarification of biological risk mechanisms 
underlying disorder risk should permit the identification 
of relevant predictive biomarkers which will ensure that 
“at risk” subjects receive prompt clinical intervention if 
required.
Key words: CCN3; Immune system; Steroid sulfatase; 
Nephroblastoma-overexpressed; Mouse; Animal model; 
Risk factor
© The Author(s) 2017. Published by Baishideng Publishing 
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Core tip: Postpartum psychosis is a severe psychiatric 
condition affecting a small proportion of women shortly 
after childbirth. The pathophysiological mechanisms 
underlying risk for the condition are extremely poorly-
defined, but may include perturbed immune function, 
altered tryptophan metabolism and serotonergic 
dysfunction. Here, I critically review evidence underlying 
these assumptions, and discuss a novel model for 
postpartum psychosis risk, involving maternal deficiency 
for the enzyme steroid sulfatase, and overexpression of 
the CCN gene family, based upon emerging data from 
a recently-developed mouse animal model. Identifying 
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Davies W. Understanding the pathophysiology of postpartum psychosis
and characterising predictive biomarkers for postpartum 
psychosis risk will help to ensure prompt clinical inter-
vention if required.
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INTRODUCTION
What is postpartum psychosis?
Postpartum, or puerperal, psychosis (PP) is a severe 
psychiatric disorder which typically manifests within days 
of childbirth in a small proportion of women (1-2 in every 
1000 new mothers)[1,2]. The main symptoms of PP include 
hallucinations and delusions, cognitive disorganisation 
and confusion, anxiety and sleep problems[1,2]; rarely, 
affected mothers may attempt to injure themselves or 
their child, with maternal suicide and infanticide observed 
in some cases. Pharmacological treatments are relatively 
efficacious if administered promptly and in combination 
with psychotherapy and psychoeducation[1,2]: These 
include a range of typical and atypical antipsychotic drugs 
and mood stabilisers (given that mood fluctuations, 
or bipolarity, may precede and/or be exacerbated by 
PP); prophylactic pharmacotherapy may also be used 
judiciously in women at high risk of PP[1,2]. 
Risk and protective factors
The single largest risk factor for PP is a personal, or 
family, history of bipolar disorder or related psychotic 
disorder (seen in about 40%-50% of PP cases[1,2]). Other 
risk factors that have been suggested as modulators of 
PP risk include: Primiparity, maternal age, stress levels 
in the puerperium, and maternal sleep problems[1-4]; 
in contrast to postpartum depression, adverse early-
life events do not appear to significantly enhance risk 
of developing PP in women with bipolar disorder[5]. The 
condition is associated with obstetric complications, 
notably pre-eclampsia[6], a potentially-damaging increase in 
maternal blood pressure. In common with other psychotic 
spectrum conditions such as schizophrenia, psychosis-
related phenotypes in the perinatal period seem to be 
higher in immigrant populations, possibly as a function 
of being exposed to new infections, or to high levels 
of stress[7]. A recent intriguing study has tentatively 
suggested that women who smoke exhibit reduced 
risk of developing PP[8], although the questions as to 
whether this association is genuine, whether cigarettes 
somehow confer biological protection, or whether the 
smoking and non-smoking groups differ on some other 
critical demographic, biological or psychological measure 
unrelated to smoking remain to be directly addressed.  
A biological basis to risk?
The temporal proximity of PP onset to childbirth, its 
high relapse rate, and its relatively stable prevalence 
and nature across societies and cultures, indicates that 
risk for the condition may be substantially influenced 
by biological factors[1,2]. The maternal body undergoes 
extreme physiological changes in the postpartum period, 
notably a massive drop in circulating oestrogens upon 
expulsion of the placenta. It has been suggested that 
abnormal sensitivity to this endocrinological disturbance 
may confer vulnerability to PP in some women[1,2], an idea 
supported by the fact that oestrogen supplementation 
may be beneficial to some patients[9,10]. The fact that 
PP is often responsive to antipsychotic treatment in-
dicates that abnormal serotonergic and/or dopaminergic 
function may play a role in its pathogenesis; there is 
a well-established link between oestrogen levels and 
serotonergic function[11]. An increasing body of literature 
has implicated immune system dysfunction in psychotic 
disorders in general[12] and in PP specifically[13], whilst 
thyroid system abnormalities[14] and other autoimmune 
conditions[15] have been reported in some cases of PP. 
Although the epidemiology, risk/protective factors, 
and comorbid phenotypes associated with PP have 
been systematically investigated and several have been 
consistently replicated (albeit by a small number of 
research groups), the molecular, cellular and neural 
pathophysiology of the condition is currently very poorly 
understood. Below, I list some contemporary approaches 
aimed at addressing this issue and their successes 
and limitations. Understanding the biological factors 
that confer PP risk will be important for identifying and 
characterising novel drug targets for more efficacious, 
less toxic, pharmacotherapy; however, given the re-
asonable efficacy of currently available medications this 
is perhaps not the main goal. A more pressing aim once 
biological risk pathways have been identified will be to 
describe predictive biomarkers which may be used to 
classify individuals at risk of the condition early in their 
pregnancy, and to ensure that they are closely monitored 
and have prompt access to appropriate clinical expertise 
and facilities if required. 
CURRENT APPROACHES TO 
UNDERSTANDING POSTPARTUM 
PSYCHOSIS AND THEIR LIMITATIONS
There are a number of diverse approaches that have 
been employed in trying to understand the patho-
physiology of PP. These investigational methods, and 
their relative advantages and limitations are summarised 
in Table 1.  
Clinical biochemistry
One conceptually-simple approach to understanding the 
biology of PP is to compare the biochemistry of patients 
diagnosed with PP with that of appropriate controls 
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(either postpartum mothers without psychosis, or non-
postpartum females). Studies to date have focussed on 
levels of tryptophan and its metabolites (i.e., precursors 
of serotonin)[16], and the immune[13] and thyroid[14] systems, 
the latter two systems being in considerable flux during 
pregnancy and in the perinatal period. The main findings 
of these studies may be summarised, respectively, as: (1) 
deficient tryptophan breakdown, and lower kynurenine 
production, is evident in women with postpartum mood 
disorders; (2) abnormally low T cell numbers, and over-
activation of the monocyte/macrophage arm of the 
immune system is evident in the postpartum period in 
women diagnosed with PP; and (3) patients with PP have 
a higher prevalence of autoimmune thyroid disease than 
controls.
Whilst this type of study undoubtedly provides clinically-
relevant knowledge about the abnormal biology asso-
ciated with PP, it is limited in several key ways. First, it 
is difficult to obtain biological samples from psychotic 
patients, particularly where these patients lack capacity 
to consent to experimental procedures, and where 
they may be socially and geographically isolated from 
individuals who can give consent on their behalf. Second, 
the biological samples that can be obtained are peripheral 
(typically blood or serum); accessibility to more relevant 
tissue from patients [brain, or even cerebro-spinal fluid 
(CSF)] is very limited or impossible. Whilst this may not 
be a major concern with regard to developing predictive 
peripheral biomarkers, the relationship between any 
peripheral tissue changes and abnormal brain function 
underlying behavioural phenotypes is difficult to chara-
cterise. Finally, biochemical measures can fluctuate 
substantially as a function of demographic variables, 
physiological and general health status, psychosocial 
factors and drug regime; hence, identifying physiological 
measures which definitively and reliably differentiate 
individuals with PP from healthy individuals, and esta-
blishing exactly how these measures correlate with 
phenotype, is extremely challenging. Moreover, there 
is the potential issue of reverse causation whereby it 
is difficult to establish unambiguously whether specific 
biochemical differences between individuals with PP and 
healthy controls are a cause or a consequence of the 
condition and its treatment.
Neuroimaging
The biochemical studies above are limited by their ability 
to directly assay brain function. The development of 
elegant neuroimaging techniques, including functional 
magnetic resonance imaging (fMRI) and Diffusion Tensor 
Imaging over the past couple of decades, has opened up 
the possibility of identifying neural substrates associated 
Investigational method Advantages of method Limitations of method
Clinical biochemistry or 
gene expression analyses
Direct assessment in patient or “at risk” 
groups
Difficult to access central nervous system; peripheral changes may not reflect 
central functional abnormalities
Possibility of identifying peripheral 
biomarkers for PP risk
Potential issues with obtaining consent for samples
Substantial fluctuation of markers with participant demographics, experiences 
and treatments
Possible issues related to reverse causation, i.e., are abnormalities a cause or 
consequence of the disorder?
Neuroimaging Direct assessment of brain structure, 
function or chemistry in patient or “at risk” 
groups
Cannot easily be performed during psychotic episodes
Substantial exclusion criteria for procedure
Limited resolution; cannot provide information on most neurochemical, 
cellular or molecular abnormalities
Substantial fluctuation of measures with participant demographics, 
experiences and treatments
Possible issues related to reverse causation, i.e., are abnormalities a cause or 
consequence of the disorder?
Genetics DNA can be readily obtained from patient 
or “at risk” groups from peripheral tissues
Low power of genome-wide studies as a consequence of low prevalence of the 
condition; possibility of false positives and negatives
DNA sequence is stable and unaffected by 
variability in patient’s circumstances
Possibility of identifying biomarkers that 
can predict risk at an early stage
Few issues with reverse causation
Porcine infanticide model Some degree of face validity Questionable relevance of animal behavioural phenotypes to PP symptoms
Direct access to brain tissue for detailed 
examination and DNA for genetic studies
Difficult and expensive to breed and maintain
Not readily amenable to pharmacological studies; predictive validity unclear
Difficult to systematically assess all brain regions
STS-inhibition mouse model Some degree of face and predictive validity Questionable relevance of animal behavioural phenotypes to PP symptoms
Direct access to brain tissue for detailed 
examination
Face and predictive validity require further confirmation
STS deficiency unconfirmed in PP cases, hence construct validity 
unsubstantiatedRelatively cheap to breed and maintain
Amenable to pharmacological and genomic 
studies
Table 1  The advantages and limitations of methods for investigating biological risk factors in individuals with postpartum psychosis
PP: Postpartum psychosis; STS: Steroid sulfatase.
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with PP vulnerability. Neuroimaging studies in this area 
are scarce, presumably due to issues with participant 
recruitment and testing. To date, no brain circuitry has 
consistently be shown to develop or function abnormally 
in cases of PP. A recent case-control study has suggested 
that individuals developing PP have a reduced anterior 
cingulate cortex (ACC) volume[17]. As the ACC plays an 
important role in cognitive and emotional processing, 
including in impulse control, decision-making and cognitive 
organisation, it represents an interesting neural candidate 
for further study. Rare cases with PP who have been 
imaged have reported altered ventricular morphology[18], 
abnormal orbitofrontal cortex reactivity[19] and structural 
abnormalities of the corpus callosum[20].
Imaging studies, like biochemical studies, are limited 
in several ways. First, for practical reasons, it is not 
possible to examine brain function during psychotic 
episodes, and this has to be assessed in “recovered”, or 
“at risk” participants - hence, the relevance of findings 
from, e.g., fMRI studies to psychotic experiences is 
questionable. Moreover, imaging measures, particularly 
“snapshot” studies, may be confounded by a patient’s 
demography, life history and comorbid diagnoses, and 
current and previous medication regimes. Finally, whilst 
neuroimaging can identify brain regions and circuits that 
may be of potential interest, and sophisticated techniques 
like magnetic resonance spectroscopy might identify 
reasonably highly spatially-resolved changes in limited 
brain neurochemistry, such approaches cannot identify 
most changes in neurochemistry, nor altered cellular or 
molecular function.
Genetics 
Psychiatric genomics has recently come of age, with 
genetic risk variants associated with psychosis risk now 
being reliably identified via genome screens in patients 
with psychotic and mood disorders such as schizophrenia 
and bipolar disorder[21]. Genetic studies offer two key 
advantages over the above approaches: First, genomic 
material (DNA) can be reliably obtained from accessible 
tissues (typically saliva or blood), and DNA sequence is 
essentially conserved between these peripheral tissues 
and the brain. Second, genetic sequence is stable 
throughout life, and unlike biochemical or brain function 
measures, is not affected by environmental, psychosocial 
or pharmacological influences.    
The robust identification of common risk variants 
that increase risk of complex psychiatric disorders by a 
small amount, or of rare variants that confer greater risk, 
necessitates the use of large sample sizes (conceivably 
up to 100000 cases to detect a high proportion of risk 
variants). For relatively common psychiatric disorders 
such as schizophrenia and bipolar disorder obtaining 
this number of cases is feasible through collaborative 
enterprises such as the Psychiatric Genomics Con-
sortium[22]. For rare disorders such as PP it is unlikely that 
such large numbers of participants can be recruited, even 
with extensive inter-institutional working. Based upon 
our existing knowledge, it seems likely that, in common 
with related mood and psychotic disorders, genetic risk 
for PP will be complex and polygenic; hence, genomic 
analyses in PP, even with several thousand cases, will be 
limited by relatively low power.
Genetic studies that have been performed in PP to 
date have employed small sample sizes (< 1000 cases), 
and hence their conclusions should be regarded with 
caution: Low power implies a high rate of both false 
positive and false negative findings. A seminal genetic 
(linkage) study in bipolar affective postpartum psychosis 
suggested evidence for significant and suggestive risk 
loci at 16p13 and 8q24 respectively[23]; the regions 
implicated contained multiple genes, many of which 
could theoretically have mediated PP risk. Efforts are 
currently underway to undertake a sufficiently-powered 
genome-wide association study (GWAS) in bipolar 
affective postpartum psychosis, but as yet these have not 
yielded significant findings. Candidate gene-led studies in 
PP have focussed upon serotonergic system genes given 
the therapeutic efficacy of antipsychotics; one study 
provided suggestive evidence for association within the 
serotonin transporter and serotonin 2A receptor genes[24]. 
However, candidate gene association studies, which focus 
upon genes of likely biological relevance to a condition, 
often have low replication rates and are inevitably 
biased by our very limited current knowledge base[25]. 
Other candidate gene association studies in PP have 
examined a number of genes important in serotonergic 
and oestrogenic signalling, and the immune response, 
but, as yet, these have yielded mixed findings with little 
consistent evidence for robust risk variants[1]. Genomic 
techniques such as exome, or even whole-genome, se-
quencing are feasible in the relatively small number of PP 
samples available, but here again, low power will make 
drawing any conclusions about the pathogenicity of any 
potentially-causal genetic variants difficult.  
Besides looking at the DNA sequence per se, insights 
into PP pathogenesis may be obtained by comparing the 
epigenome or gene expression profiles in individuals with 
PP and controls. One such study focussed upon microRNAs 
known to regulate the immune response and demonstrated 
altered expression of miR-146a and miR-212 in patients 
with PP relative to healthy controls[26]. However, whether 
these changes were a cause or consequence of the 
disorder (and associated medications) is unclear. Moreover, 
like with candidate gene association studies, expression 
studies focussing on just a handful of pre-selected genes 
provide limited information on the specificity of the changes 
or on general risk pathways; for example, it could feasibly 
be the case that the expression of a large proportion of 
microRNAs is perturbed in PP. 
The porcine infanticide model of PP
A further approach towards understanding the biological 
basis of PP risk is through the use of animal models. 
Animal models permit a degree of experimental control 
that cannot be achieved in clinical, or other human, 
Davies W. Understanding the pathophysiology of postpartum psychosis
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studies and allow procedures that would be ethically 
prohibited in humans to be conducted; however, there is 
some resistance to the use of animals, and particularly 
non-primate species, for modelling complex psychiatric 
phenotypes characterised by deficits in “uniquely-
human” aspects of behaviour and cognition. The first 
published animal model for PP is the infanticidal sow pig, 
which exhibits several epidemiological, behavioural and 
endocrinological traits associated with the condition[27]. 
An early quantitative trait locus (QTL) study in this 
model identified four possible genomic loci of interest 
on chromosomes 2, 10 and X, corresponding to human 
chromosomal loci 5q14.3-15, 1q32, Xpter-Xp2.1, and 
Xq2.4-Xqter respectively[27]; an independent linkage 
study confirmed an association between X-linked loci and 
maternal aggression, and suggested regions of interest 
on chromosomes 2, 6, 14 and 15[28]. Examination of 
hypothalamic gene expression in the maternal infanticide 
model identified multiple genes, the expression of which 
was altered in pigs showing aberrant behaviour; several 
of these mapped to the previously-implicated QTL 
regions [of particular note were the HTR2C (serotonin 
receptor 2C), DRD2 (dopamine receptor 2) and PRL 
(prolactin) genes, the first two encoding antipsychotic drug 
targets[29]]. A genome-wide association study in this model 
indicated candidate regions on porcine chromosomes 3, 
4 and 15, syntenic with human chromosomal regions 
implicated in bipolar disorder and postpartum psychosis 
(including 16p13)[30], whilst a candidate gene association 
study suggested preliminary evidence for association 
with oestrogen receptor (ESR1), excitatory amino acid 
transporter 2 (EAAT2) and dopamine receptor 1 (DRD1) 
genes, but not HTR2C[31].
The fact that the pig model described above shows 
some superficial phenotypic similarities to patients with 
PP (“face validity”), and that it indicates genomic regions, 
and specific gene candidates, of possible functional 
relevance, suggests that it may represent a reasonable 
model for PP. However, it should be acknowledged 
that the model is compromised in a number of ways 
which may limit its utility. First, there is a relatively poor 
correlation between the clinical and animal behavioural 
profiles, in that the vast majority of women with PP are 
not aggressive, and even those who are aggressive 
will not attempt infanticide. Second, this large animal 
model is difficult and expensive to breed, maintain, and 
analyse experimentally. Of particular note, it is difficult 
to test whether the infanticide phenotype is sensitive 
to antipsychotic administration - hence it is difficult 
to determine the extent to which this phenotype is 
analogous to PP, and to assess whether or not the model 
has any degree of predictive validity. Another main issue 
is that, because the brain of the pig is relatively large, 
it is difficult to investigate all regions where abnormal 
activity may be observed; whilst previous work has 
understandably focused on the hypothalamus given its 
known role in maternal behaviour, there is, as yet, little 
convincing evidence for impaired hypothalamic function 
in PP cases.
PATHWAYS TO PROGRESS
Despite decades spent studying the illness, and the 
availability of cutting-edge experimental techniques and 
research hardware, we are still far from understanding 
the biological and psychological risk factors underpinning 
PP and hence how to identify women at greatest risk for 
the condition. Below, I briefly outline what I believe is 
required in order to make progress in this area over the 
next decade.    
Perhaps the main factor hindering progress in PP 
research is sample size. It is now well recognised in 
psychiatry that groups from around the world must 
collaborate in order to generate an adequately-powered, 
consistently and deeply-phenotyped cohort of patients 
(and their affected and non-affected relatives) in which 
genetic, biochemical and neuroimaging analyses can be 
undertaken; such a large sample will permit factors such 
as drug treatment, demography and symptomatology to 
be covaried for, and hence for robust genotype-biology-
phenotype correlations to be ascertained. There are 
ongoing collaborative efforts in the field of PP research 
involving centres of excellence across Europe and the 
United States, and these should soon begin to bear fruit. 
One research area that has been relatively neglected 
to date is deciphering the fundamental psychological 
processes that distinguish mothers who develop PP from: 
(1) those who have bipolar disorder and do not develop 
the condition; or (2) from healthy mothers. Specifying 
how “at risk” women differ from “protected” women 
on measures of behaviour and cognition, may feasibly 
permit the development of a simple screening test to be 
applied prior to childbirth, and may provide clues as to 
underlying neurobiology.  
Even with larger numbers of cases available for 
genome-wide genetic analyses, there is a strong possibility 
that only a handful of polymorphisms or mutations 
associated with PP risk will be identified, and that many 
will not reach genome-wide levels of significance after 
the requisite stringent multiple testing corrections. 
Hence, there may still be a role for sensible candidate 
gene association studies comparing variant frequency 
in cases and controls, where higher levels of alpha (as a 
consequence of reduced multiple testing) are more likely 
to give rise to statistically significant findings. However, 
as discussed above, traditional candidate gene studies 
based upon theoretical causal or therapeutic mechanisms 
have frequently been shown to be irreproducible, or to 
give rise to findings of a much smaller magnitude than 
initially suspected[25,32]. Moreover, genome-wide association 
studies have repeatedly demonstrated that genetic 
variants robustly associated with disorder risk are often 
poorly-annotated and have unknown effects on biology, 
and hence would not have been prioritised in candidate-
led approaches[32]. Bearing in mind these caveats, 
proposals for candidate PP genes should be supported by 
multiple converging lines of evidence, and should ideally 
exhibit both positional and functional relevance. In the 
following section, I describe a candidate gene backed by 
Davies W. Understanding the pathophysiology of postpartum psychosis
82 June 22, 2017|Volume 7|Issue 2|WJP|www.wjgnet.com
such evidence. 
There is also clearly a need for more experimentally-
tractable animal and cellular models, in which molecular, 
cellular and circuit mechanisms that may influence PP 
risk can be characterised. In terms of animal models, 
ideally these should be available to be tested in large, 
well-defined batches, be neurobiologically-amenable, 
and exhibit some degree of face, construct and predictive 
validity (the latter in contrast to the porcine infanticide 
model). In terms of cellular models, the advent of induced 
pluripotent stem cell technology technology now means 
that “pathological” samples such as brain cell cultures 
can ultimately be generated from patient fibroblast, or 
other peripheral, cells[33]. Any data generated from in vitro 
studies in which derived-brain cells are examined in 
isolation, should be extrapolated cautiously given that 
PP risk, in common with the risk of related psychiatric 
conditions such as schizophrenia and depression, is likely to 
be modulated by complex ongoing interactions between 
a multitude of intra-brain and extra-brain (e.g., hormonal, 
placental or immune system) factors[34]. 
A NEW CANDIDATE GENE
I have previously proposed, based upon numerous lines 
of clinical and basic scientific evidence, that maternal 
deficiency for the enzyme steroid sulfatase, encoded by 
the X-linked STS gene, may represent one candidate risk 
mechanism for PP[35]. The STS enzyme cleaves sulfate 
groups from a variety of steroid hormones, notably dehy-
droepiandrosterone sulfate (DHEAS), thus allowing them 
to be used as precursors for a variety of androgens and 
oestrogens; hence it is a key modulator of the steroid 
hormone axis. There are a number of criteria that candi-
date genes and pathways for PP may be expected to 
meet based upon our existing knowledge; the STS gene 
and the processes which it modulates meet many of 
these.
One might expect the candidate system to be in 
flux in the postpartum period, and to influence immune 
function at this time; in mice, and perhaps also in man, 
brain levels of STS are elevated specifically shortly after 
giving birth[36]. In healthy women, reduced levels of 
serum DHEA in the postpartum period are associated 
with activation of the immune system[37]; conceivably, 
in STS-deficient women, abnormally low levels of post-
partum DHEA (as a consequence of impaired DHEAS 
desulfation) may result in hyperactivation of the immune 
system. 
The steroid hormone axis has repeatedly been im-
plicated in the pathogenesis of PP given the sudden drop 
in circulating oestrogen levels in the mother following 
birth, and the suspected protective effects of oestrogens 
against psychosis[38]; indeed, early candidate gene 
association studies focussed upon those regions of the 
genome thought to be regulated by oestrogens[39]. STS 
is a key player within this axis. STS is highly expressed 
in key reproductive tissues (testis, mammary gland, 
placenta, uterus, brain[40]) and hence its dysfunction may, 
a priori, be expected to impact upon normal reproductive 
physiology. Recently, placental mis-expression of the STS 
gene has been implicated in pre-eclampsia risk[41]. It is 
plausible that in STS-deficient mothers, where baseline 
oestrogen levels may already be low[42], expulsion of the 
oestrogenic placenta precipitates psychosis vulnerability. 
There is also some evidence that women who are carriers 
for STS mutations, and who are STS-deficient, are at 
increased risk of psychological abnormalities (unpublished 
results) and of delayed, or prolonged labour, and related 
obstetric complications[43]; such complications, and the 
accompanying psychological stress, may be one pre-
cipitant of postpartum psychiatric distress, although a 
specific link to PP remains unconfirmed[1,44].  
In the developing and adult brain, STS is expressed in 
regions implicated in postpartum psychosis. Specifically, 
it is highly expressed in the thalamus (involved in the 
integration and usage of sensory information) and through-
out the cortex (including the cingulate cortex)[45,46]; it is 
also highly expressed in the hypothalamus, and outside 
the brain in the thyroid gland[45,46]. Hence, its absence 
may feasibly give rise to abnormal hypothalamic-pituitary-
adrenal or hypothalamic-pituitary-thyroid function, con-
sistent with notions of an abnormal stress response, or 
thyroid pathology, in cases of PP. 
Parallel clinical and animal model studies have demon-
strated that STS deficiency (or genetic variation within 
STS) gives rise to behavioural phenotypes of relevance to 
PP including psychosis, cognitive disorganisation, anxiety, 
depression and, rarely, aggression (unpublished results 
and ref.[46-49]). Moreover, there is a positive correlation 
between serum levels of DHEAS and psychoticism (anxiety, 
paranoia, psychosis) in healthy women and women ex-
hibiting postpartum psychiatric distress[50,51]. Data from 
genetic and pharmacological rodent models suggest that 
deficiency for STS may impact upon neurochemistry 
of relevance to psychosis vulnerability including altered 
levels of hippocampal serotonin (and Htr2c receptors) 
and acetylcholine[52,53].    
Finally, STS was explicitly suggested as a candidate 
gene underlying significant X-linked QTLs in the porcine 
maternal infanticide model of PP[27].  
INSIGHTS FROM A NEW MOUSE MODEL
The only existing animal model for PP, the porcine ma-
ternal infanticide model, is sub-optimal. We have recently 
attempted to develop a more experimentally-tractable 
mouse model for the condition, based upon the idea that 
maternal steroid sulfatase deficiency is a putative risk 
factor[54]. 
Briefly, we showed that pharmacological inhibition 
of the steroid sulfatase enzyme in new mouse mothers 
resulted in behavioural, endocrinological and genetic 
phenotypes partially mirroring those seen in PP (“face 
validity”). Whilst STS inhibition did not affect gross health, 
maternal behaviours or activity, it did have subtle effects on 
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exploration of the elevated plus maze (increased rearing 
and reduced latency to enter the exposed open arms) and 
the startle response (reduced with enzyme inhibition); 
a reduced startle response is a feature of patients with 
bipolar disorder[55]. These observations support the notion 
of STS as a modulator of postpartum maternal behaviour. 
STS inhibition did not seem to influence levels of the 
main stress hormone corticosterone in mice, consistent 
with data indicating that women with PP show normal 
cortisol levels[56].  
Previous work had suggested that a small genomic 
region on mouse chromosome 15 harboured a QTL 
influencing rearing and open arm latency measures in the 
elevated plus maze[57]; excitingly, this region of chromo-
some 15 was syntenic with human chromosome 8q24, 
a region implicated in PP pathogenesis by linkage[23]. 
Expression screening of the small number of genes within 
the mouse chromosome 15 interval revealed just one, 
Nov/Ccn3, whose expression was significantly altered 
(upregulated) in STS-inhibited brain; the expression of 
two other genes from the Ccn family (Ctgf/Ccn2 and 
Wisp1/Ccn4), as well as genes whose products may be 
co-regulated with Nov/CCN3 (Arhgdig, Adcy8 and Ccl2) 
was also increased in STS-inhibited brain tissue[54]. 
An advantage of the mouse model is that it is possible 
to test whether putative PP-relevant behavioural and 
molecular features are sensitive to antipsychotic admini-
stration, i.e., to test whether it has potential predictive 
validity. We showed that administration of clinically-
relevant doses of the atypical antipsychotic ziprasidone 
reverses the deficient startle response, and tempers the 
over-expression of Nov/Ccn3 in the STS-inhibited mouse, 
indicating that these facets of the model may be relevant 
to psychotic pathophysiology[54]. 
Although the STS-inhibited mouse shows some degree 
of promise as a model for PP, its face validity needs to be 
defined more thoroughly. For example, does it show the 
abnormalities in the tryptophan-kynurenine pathways 
and immune system that have been reported in PP 
cases? One limitation of the current pharmacological 
model is that steroid sulfatase is solely inhibited in the 
postpartum period - if STS deficiency is truly a risk factor 
for PP, it would likely be genetic in origin, and operate 
throughout life (including pregnancy and the postpartum 
period). Hence, it would be useful to examine the 
behaviour and physiology of new mouse mothers that 
lack one (or both) functional STS alleles, and hence have 
reduced constitutive STS expression; such knockout 
mice have historically proved difficult to generate due to 
the complex genomic architecture around the STS locus, 
but this difficulty may potentially be overcome with new 
genetic engineering technologies such as CRISPR. 
A NEW PATHWAY TO PATHOLOGY AND 
TREATMENT?
The new mouse model described above indicates, on 
the basis of analyses agnostic to gene function, that 
dysregulation of the CCN gene family arising downstream 
of dysfunction of the STS axis may be implicated in PP 
risk. Is this a reasonable concept? If so, can this evaluation 
suggest molecular, cellular and neural pathways that could 
be perturbed in PP and that could feasibly be targeted 
via re-purposing of existing drugs, or through developing 
new drugs?
The CCN gene family encodes a number of secreted 
extracellular matrix-associated proteins that are highly-
expressed in the brain[58]; impaired function of the ex-
tracellular matrix, and the subsequent abnormal cell-
cell interactions, have recently received attention as a 
possible pathophysiological mechanism in a number of 
mood disorders[59]. This gene family is also known to be 
important in female reproductive function[60], exhibits 
dynamic brain expression throughout pregnancy and the 
puerperium[61], and modulates Notch and Wnt signalling 
pathways[57] that are disrupted in bipolar disorder[62] 
and cases of postpartum psychiatric disturbance[63]. 
Interestingly, the expression of CCN family members may 
also be altered by the administration of substances that 
induce psychosis-like states[64,65], by social stress[66] and 
by small molecules including cytokines and serotonin[67] 
suggesting these members as possible mediators of 
analogues of psychosis.
CCN3 is of particular interest as a candidate modulator 
of PP risk given the location of the associated gene directly 
under the 8q24 linkage peak. There is also emerging evidence 
from a study in human female (cervical cancer) cells that 
STS and DHEA can directly influence the expression of the 
integrin β1 molecule[68], a known interactor with CCN3 in 
the brain and a putative mediator of CCN3-induced effects 
on cytokine secretion[69].
The CCN3 protein exhibits a variety of additional 
features that strengthen its candidacy. First, it regulates 
intracellular calcium signalling[70] a process that goes 
awry in both bipolar disorder[71] and PP[72]. Second, it is highly 
expressed in the brain’s cortex and limbic system[58], and 
its expression is dampened by circulating oestrogens[73]. 
It is apparently a regulator of axonal outgrowth of callosal 
projection neurons[74], a finding of interest in light of possible 
corpus callosum abnormalities in cases of PP[20]. The fact 
that CCN3 modulates placental angiogenesis[60], that the 
associated gene is located 70kb from a GWAS hit for 
hypertension[75] and that it, and its family members, are 
regulated by thyroid hormone derivatives in the cortex of 
the brain[76], is consistent with the epidemiological studies 
showing overlap between PP, pre-eclampsia and thyroid 
abnormalities. Given the preliminary findings regarding 
a potential attenuation effect of smoking on PP risk, it 
is interesting to note that the CCN3 gene lies close to a 
single nucleotide polymorphism nominally associated 
with smoking cessation[77], and that in female mouse 
tissues Ccn3 expression is reduced upon exposure to 
cigarette smoke[78]. The protein DDR1 is a putative 
receptor mediating CCN3 signalling[79]; there is some 
evidence suggesting association of genetic variants within 
DDR1 with psychotic illness[80,81].
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Finally, converging evidence from a genetic mouse 
model is consistent with the notion that Ccn3 over-
expression is associated with abnormal maternal be-
haviour. Specifically, wildtype mouse mothers carrying 
pups with genetic modifications which affect placental 
(spongiotrophoblast) function exhibit abnormal maternal 
and anxiety-related behaviours in the postpartum period 
and significantly increased hippocampal Nov/Ccn3 gene 
expression[54,82]; this finding is intriguing as it suggests the 
possibility that the secretion (or lack thereof) of one or 
more circulating factors from the placenta can indirectly 
affect brain expression of Nov/Ccn3, and subsequently 
maternal behaviour. The spongiotrophoblast is involved 
in the synthesis and secretion of multiple compounds 
which have been shown to influence maternal behaviour 
in rodent models and which may plausibly mediate this 
effect (e.g., placental lactogens and pregnancy-specific 
glycoproteins[83]). Interestingly, in humans, placental 
lactogen is secreted by the syncytiotrophoblast of the 
placenta[84], a site of high STS expression[85].  
An integrated model showing how PP risk may 
conceivably be influenced by STS deficiency, placental 
dysfunction, and disruption to CCN family members 
based upon current knowledge is presented in Figure 
1. This model may be updated and refined as new data 
emerge from avenues including larger genomic screens, 
hypothesis-free gene expression screens in model 
systems, and physiological measurements in patients 
with PP. The model makes several readily-testable clinical 
predictions for PP cases relative to control subjects: (1) 
there will be an excess of genetic variants that reduce STS 
function and enhance CCN3 expression; (2) there will be 
an increased DHEAS:DHEA tissue ratio; and (3) there will 
be elevated levels of CCN3 in accessible fluids including 
serum, cerebrospinal fluid and urine[86]. In parallel to these 
clinical studies, we could potentially demonstrate whether 
or not CCN3 contributes significantly to abnormal maternal 
behavioural phenotypes in mice by administering an 
STS inhibitor to wildtype mice and readily-available Ccn3 
knockout mice[87], with the prediction being that wildtype 
mice would exhibit behavioural abnormalities whereas 
knockout mice would not. 
Should CCN family member over-expression be 
confirmed as a PP risk factor by future clinical and basic 
Abnormal behaviour in postpartum period
Hallucinations, delusions, anxiety, cognitive disorganisation, mood problems. Possible suicidal or infanticidal ideation, and completed suicide or 
infanticide 
Altered function of CCN gene family members 
and interactors in brain and other tissues (e.g. , 
placenta)
Disrupted extracellular matrix function, and 
abnormal signalling to cytoplasm via , e.g. , 
Notch and integrin pathways
Placental dysfunction
Aberrant secretion of signalling molecules 
such as oestrogens and placental lactogens
Environmental risk factors in 
postpartum period
E.g. , psychosocial stressors, sleep 
disruption
"At risk" personality and psychological traits
including bipolar disorder
Altered brain anatomy and physiology
Abnormal development of multiple brain regions including thalamus, 
cortex, corpus callosum and hypothalamus
Disruption of serotonergic and cholinergic systems
Dysfunction of endocrine organs
Aberrant secretion of signalling molecules such 
as oestrogens and thyroid hormones
Baseline genetic and environmental risk factors
Possession of multiple genetic risk variants and exposure to general environmental risk factors
Figure 1  A revised model for postpartum psychosis risk. We suggest that multiple genetic risk variants (potentially influencing STS and CCN family member 
function), in combination with environmental risk factors, adversely affect the function of multiple endocrine organs (notably placenta and thyroid gland) and increase 
expression of CCN family members in brain and placenta, to elicit functional changes in brain architecture and neurochemistry which predispose to postpartum 
psychosis risk. This risk may be further exacerbated by acute environmental risk factors acting within the postpartum such as psychosocial stressors (plausibly also 
acting via CCN-mediated pathways). Putative and well-characterised protective factors such as smoking and antipsychotic administration respectively could potentially 
exert their effects via normalisation of CCN family member function. 
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studies, it may be amenable to pharmacological ameliora-
tion by, amongst other approaches, antibody-targeting 
or knockdown strategies[88]; such interventions may have 
therapeutic benefits and offer an alternative to more 
conventional mood stabiliser and antipsychotic approaches. 
CONCLUSION
Numerous features of postpartum psychosis (notably 
its low prevalence, its high degree of heterogeneity, its 
relative unpredictability and a lack of relevant animal and 
cellular models) make understanding its pathophysiology 
difficult. Whilst research to date has provided tantalising 
hints at pathways and systems that may be perturbed in 
the condition, the questions as to whether or not they are 
truly pathogenic remains to be addressed. Undoubtedly, 
there are many more risk pathways to be discovered.
To make meaningful progress in understanding the 
molecular, cellular, neural and psychological mecha-
nisms underlying PP risk it will be necessary to adopt 
a converging experimental approach comprising large-
scale genetic (association, copy number variations and 
sequencing), gene expression and genetic neuroimaging 
studies, clinical studies correlating behavioural phenotypes 
with physiological markers of immune, neurochemical 
and neuroendocrine dysfunction, and animal (pig and 
mouse) and cellular (e.g., induced pluripotent stem cells) 
model studies, bearing in mind the many caveats raised 
above. Importantly, hypothesis-free approaches such 
as the genomic and animal/cellular model approaches 
may identify non-obvious risk pathways which can then 
be followed up in more focussed clinical analyses. The 
prioritisation of candidate pathways may be informed by 
work examining the physiology of related conditions and 
behaviours including bipolar disorder, other postpartum 
mood disorders, pre-eclampsia and smoking.
A main goal in PP research is to identify biomarkers 
within easily accessible tissues that can be sampled 
before, or during, pregnancy (e.g., blood, saliva) that 
can accurately predict risk, a substantial challenge for 
such a rare condition; early identification of “at risk” 
individuals should facilitate rapid access to appropriate 
facilities and medical care (including close monitoring, 
administration of psychological or pharmacological treat-
ments, and counselling). The experimental analyses 
proposed above are likely to result in the identification 
and characterisation of such biomarkers. 
A recent study has shown that the expression of 
Nov/Ccn3 in rat tissues is sensitive to the administration 
of the mood-stabilising drug lithium which has clinical 
efficacy in some cases of PP[89].
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